Skip to main content

Cullinan Therapeutics, Inc.

corporate_fare Company Profile

Cullinan Therapeutics, Inc.

CGEM·NASDAQ·Life Sciences·CIK 0001789972

We are a biopharmaceutical company focused on developing therapies for autoimmune diseases and cancer. We specialize in T cell engagers, which are used in oncology and are now being applied to autoimmune diseases. Our clinical-stage pipeline is built on a scientific approach and innovation, aiming to deliver new standards of care for patients. In Immunology, we are developing CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases. The Phase 1 OUTRACE Program is evaluating CLN-978 in patients with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and Sjögren's disease (SjD). The OUTRACE SLE Study is a global Phase 1 clinical trial for moderate to severe SLE. The OUTRACE RA Study is a Phase 1 clinical trial for active, difficult-to-treat RA, ongoing in Europe. The OUTRACE SjD Study is a global Phase 1 clinical trial for active, moderate to severe Sjögren's disease. We are also developing Velinotamig, a BCMAxCD3 bispecific T cell engager for autoimmune diseases. Chongqing Genrix Biopharmaceutical Co., Ltd. (Genrix), our licensor, is conducting a Phase 1 clinical trial in China for autoimmune diseases, starting with SLE and planning future expansion. We plan to use this data to accelerate global clinical development and will conduct all further development of velinotamig in autoimmune diseases after Genrix completes its Phase 1 trial. In Oncology, our program includes CLN-049, a FLT3xCD3 bispecific T cell engager.

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 25 items for CGEM at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-12, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 12 rated 8 or above. Recent SEC coverage for CGEM spans 8-K, 10-Q.

Recent high-impact activity:

  • Zipalertinib NDA Filed Under FDA Real-Time Review for First-Line EGFR ex20ins NSCLC
  • Velinotamig Drives Complete Renal Responses in Refractory SLE; 8 of 9 Patients Improve
  • Zipalertinib Shows 30% Intracranial Response Rate in Brain-Metastatic EGFR NSCLC
  • Cullinan Initiates NDA Submission for Zipalertinib Combo in First-Line EGFR ex20ins NSCLC Under FDA RTOR
  • Cullinan Sets Q4 Data Readouts for Three T Cell Engagers, FDA Meeting Clears Path for CLN-049 Phase 2

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$219.88M
Op. Cash Flow
-$175.75M
Free Cash Flow
-$175.8M
Operating Income
-$241.65M
Cash & Equivalents
$88.33M
Debt / Equity
0.00×
Shares Outstanding
60.24M sh
Source: 10-K · filed 2026-03-10 · accession 0001193125-26-099362

Short Interest & Short Volume

13.33 days to cover

FINRA reported short interest of 7,928,668 shares in CGEM as of the October 30, 2026 settlement, a 3.8% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 20, 2026, 57.6% of CGEM volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)7,928,668 shares as of October 30, 2026
Change vs prior period▲ 3.8%
Days to cover13.33 at avg daily volume of 594,711
Daily short volume (FINRA facilities)57.6% of 260,470 shares on November 20, 2026
5-day average short volume50.0%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Browse all tickers starting with C →
$8.96 +0.79% today
52-week range · as of 2026-10-01 $5.68 – $23.19
Market cap
$577.15M
Volume
1M (1.1× avg)
3-mo avg 887.9K
Live data · 2026-11-21 17:06 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CGEM - Latest Insights

CGEM
Nov 12, 2026, 4:30 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $10.35
Real-time Price: $8.96 info
Change: -$1.39 (-13%) info
Market Cap: $577.147M info
CGEM
Nov 08, 2026, 10:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.51
Real-time Price: $8.96 info
Change: -$2.55 (-22%) info
Market Cap: $577.147M info
CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $8.96 info
Change: -$4.39 (-33%) info
Market Cap: $577.147M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $8.96 info
Change: -$5.59 (-38%) info
Market Cap: $577.147M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $8.96 info
Change: -$7.92 (-47%) info
Market Cap: $577.147M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $8.96 info
Change: -$11.64 (-57%) info
Market Cap: $577.147M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $8.96 info
Change: -$12.15 (-58%) info
Market Cap: $577.147M info
CGEM
Aug 12, 2026, 7:30 PM EDT
Source: BusinessWire
Importance Score:
9
Price at Filing: $19.60
Real-time Price: $8.96 info
Change: -$10.64 (-54%) info
Market Cap: $577.147M info
CGEM
Aug 06, 2026, 7:10 AM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $17.36
Real-time Price: $8.96 info
Change: -$8.40 (-48%) info
Market Cap: $577.147M info
CGEM
Aug 06, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $17.36
Real-time Price: $8.96 info
Change: -$8.40 (-48%) info
Market Cap: $577.147M info
CGEM
Jun 10, 2026, 7:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.38
Real-time Price: $8.96 info
Change: -$4.42 (-33%) info
Market Cap: $577.147M info
CGEM
Jun 08, 2026, 6:33 AM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $14.81
Real-time Price: $8.96 info
Change: -$5.85 (-40%) info
Market Cap: $577.147M info
CGEM
Jun 08, 2026, 6:32 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.81
Real-time Price: $8.96 info
Change: -$5.85 (-40%) info
Market Cap: $577.147M info
CGEM
Jun 06, 2026, 5:32 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $13.58
Real-time Price: $8.96 info
Change: -$4.62 (-34%) info
Market Cap: $577.147M info
CGEM
May 26, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $14.00
Real-time Price: $8.96 info
Change: -$5.04 (-36%) info
Market Cap: $577.147M info
CGEM
May 19, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $15.24
Real-time Price: $8.96 info
Change: -$6.28 (-41%) info
Market Cap: $577.147M info
CGEM
May 18, 2026, 5:33 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $14.87
Real-time Price: $8.96 info
Change: -$5.91 (-40%) info
Market Cap: $577.147M info
CGEM
May 18, 2026, 5:30 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.87
Real-time Price: $8.96 info
Change: -$5.91 (-40%) info
Market Cap: $577.147M info
CGEM
May 07, 2026, 7:08 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $15.15
Real-time Price: $8.96 info
Change: -$6.19 (-41%) info
Market Cap: $577.147M info
CGEM
May 07, 2026, 7:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.15
Real-time Price: $8.96 info
Change: -$6.19 (-41%) info
Market Cap: $577.147M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets